Dihydropyrimidine dehydrogenase deficiency

impact of pharmacogenetics on 5-fluorouracil therapy.

Adam Lee, Hany Ezzeldin, Jeanne Fourie, Robert B Diasio

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Through the use of pharmacogenetic studies, interindividual variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemotherapy has been linked to the rate-limiting enzyme in the drug's catabolic pathway, known as dihydropyrimidine dehydrogenase (DPD). This pharmacogenetic syndrome, known as "DPD deficiency," results in excessive amounts of 5-FU available to be anabolized to its active metabolites and is relatively undetectable by clinical observation prior to 5-FU administration. Extensive studies have associated both profound and partial deficiency in DPD activity with severe, unanticipated toxicity after 5-FU administration, while research on the molecular basis behind DPD deficiency has been linked to various sequence variants of the DPYD gene. Due to the widespread use of 5-FU, the severity of toxicity associated with DPD deficiency, and the prevalence of DPD deficiency in the population, extensive research is continually being performed to develop quick and accurate phenotypic and genotypic assays suitable for clinical settings that would allow clinicians to identify patients susceptible to adverse 5-FU reactions.

Original languageEnglish (US)
Pages (from-to)527-532
Number of pages6
JournalClinical advances in hematology & oncology : H&O
Volume2
Issue number8
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Dihydropyrimidine Dehydrogenase Deficiency
Pharmacogenetics
Fluorouracil
Therapeutics
Dihydrouracil Dehydrogenase (NADP)
Research
Observation
Drug Therapy
Enzymes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Dihydropyrimidine dehydrogenase deficiency : impact of pharmacogenetics on 5-fluorouracil therapy. / Lee, Adam; Ezzeldin, Hany; Fourie, Jeanne; Diasio, Robert B.

In: Clinical advances in hematology & oncology : H&O, Vol. 2, No. 8, 08.2004, p. 527-532.

Research output: Contribution to journalArticle

@article{3e111a48caed4bc0abcdcc7e4be17af6,
title = "Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.",
abstract = "Through the use of pharmacogenetic studies, interindividual variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemotherapy has been linked to the rate-limiting enzyme in the drug's catabolic pathway, known as dihydropyrimidine dehydrogenase (DPD). This pharmacogenetic syndrome, known as {"}DPD deficiency,{"} results in excessive amounts of 5-FU available to be anabolized to its active metabolites and is relatively undetectable by clinical observation prior to 5-FU administration. Extensive studies have associated both profound and partial deficiency in DPD activity with severe, unanticipated toxicity after 5-FU administration, while research on the molecular basis behind DPD deficiency has been linked to various sequence variants of the DPYD gene. Due to the widespread use of 5-FU, the severity of toxicity associated with DPD deficiency, and the prevalence of DPD deficiency in the population, extensive research is continually being performed to develop quick and accurate phenotypic and genotypic assays suitable for clinical settings that would allow clinicians to identify patients susceptible to adverse 5-FU reactions.",
author = "Adam Lee and Hany Ezzeldin and Jeanne Fourie and Diasio, {Robert B}",
year = "2004",
month = "8",
language = "English (US)",
volume = "2",
pages = "527--532",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "8",

}

TY - JOUR

T1 - Dihydropyrimidine dehydrogenase deficiency

T2 - impact of pharmacogenetics on 5-fluorouracil therapy.

AU - Lee, Adam

AU - Ezzeldin, Hany

AU - Fourie, Jeanne

AU - Diasio, Robert B

PY - 2004/8

Y1 - 2004/8

N2 - Through the use of pharmacogenetic studies, interindividual variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemotherapy has been linked to the rate-limiting enzyme in the drug's catabolic pathway, known as dihydropyrimidine dehydrogenase (DPD). This pharmacogenetic syndrome, known as "DPD deficiency," results in excessive amounts of 5-FU available to be anabolized to its active metabolites and is relatively undetectable by clinical observation prior to 5-FU administration. Extensive studies have associated both profound and partial deficiency in DPD activity with severe, unanticipated toxicity after 5-FU administration, while research on the molecular basis behind DPD deficiency has been linked to various sequence variants of the DPYD gene. Due to the widespread use of 5-FU, the severity of toxicity associated with DPD deficiency, and the prevalence of DPD deficiency in the population, extensive research is continually being performed to develop quick and accurate phenotypic and genotypic assays suitable for clinical settings that would allow clinicians to identify patients susceptible to adverse 5-FU reactions.

AB - Through the use of pharmacogenetic studies, interindividual variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemotherapy has been linked to the rate-limiting enzyme in the drug's catabolic pathway, known as dihydropyrimidine dehydrogenase (DPD). This pharmacogenetic syndrome, known as "DPD deficiency," results in excessive amounts of 5-FU available to be anabolized to its active metabolites and is relatively undetectable by clinical observation prior to 5-FU administration. Extensive studies have associated both profound and partial deficiency in DPD activity with severe, unanticipated toxicity after 5-FU administration, while research on the molecular basis behind DPD deficiency has been linked to various sequence variants of the DPYD gene. Due to the widespread use of 5-FU, the severity of toxicity associated with DPD deficiency, and the prevalence of DPD deficiency in the population, extensive research is continually being performed to develop quick and accurate phenotypic and genotypic assays suitable for clinical settings that would allow clinicians to identify patients susceptible to adverse 5-FU reactions.

UR - http://www.scopus.com/inward/record.url?scp=33747169515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747169515&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 527

EP - 532

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 8

ER -